You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cell Therapies
315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508
Free

Authors

Citation

Ball M, Kremp M, Qureshi R, et al
315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0315

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.